Drug Trial Radar · NCT06668064
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Jul 13, 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
- Wet Age Related Macular Degeneration
- wAMD
Interventions
EYP-1901Drug
Intravitreal Injection
Aflibercept (2.0 mg)Drug
Intravitreal Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average change in best corrected visual acuity (BCVA)Time frame: Weeks 52 and 56
Locations
76 sites in 1 country. Site status is shown where the registry gives one.
Retinal Research Institute, LLC
Phoenix, Arizona
Retina Partners of Northwest Arkansas
Springdale, Arkansas
California Retina Consultants
Bakersfield, California
Retina Vitreous Associates Medical Group
Beverly Hills, California
Macula and Retina Institute
Glendale, California
Retina Consultants San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
Retinal Consultants Medical Group
Sacramento, California
Bay Area Retina Associates
Walnut Creek, California
American Institute of Research
Whittier, California
RSC Research, PLLC
Denver, Colorado
Eye Center of Northern Colorado, PC
Fort Collins, Colorado
Advanced Vision Institute
Longmont, Colorado
Connecticut Eye Consultants, P.C.
Danbury, Connecticut
SightSera Clinical Research LLC
Greenwich, Connecticut
Retina Group of New England, PC
Waterford, Connecticut
Advanced Research, LLC
Deerfield Beach, Florida
Florida Retina Consultants
Lakeland, Florida
Florida Retina Institute
Orlando, Florida
Retina Specialty Institute
Pensacola, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
MedEye Associates
South Miami, Florida
Retina Specialists of Tampa
Tampa, Florida
Retina Vitreous Associates of Florida
Tampa, Florida
Center for Retina & Macular Disease
Winter Haven, Florida
Gerogia Retina
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Retina Associates
Elmhurst, Illinois
University Retina and Macula Associates
Lemont, Illinois
Midwest Eye Institute
Carmel, Indiana
Retina Associates LLC
Lenexa, Kansas
Maine Eye Center
Portland, Maine
The Retina Care Center
Baltimore, Maryland
Retina Groups of Washington
Chevy Chase, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Retina Specialists
Towson, Maryland
Ophthalmic Consultants of Boston OCB - Boston
Boston, Massachusetts
New England Retina Consultants
Springfield, Massachusetts
Retina Associates of Michigan
Grand Blanc, Michigan
Foundation for Vision Research
Grand Rapids, Michigan
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.